Crizotinib delivery improves when utilizing hybrid nanoparticles for lung cancer treatment and shows promising in-vitro results.
The study evaluates the effectiveness through in-vitro experiments on multiple cell lines, yielding a significant enhancement in drug delivery mechanisms.
Observational analysis details the design and optimization of hybrid nanoparticles for targeted treatment of lung cancer.
This approach may lead to more effective therapies for lung cancer, highlighting the need for advanced delivery systems.